Differential Immune Response to Bioprosthetic Heart Valve Tissues in the α1,3Galactosyltransferase-Knockout Mouse Model

dc.contributor.authorCasós, Kelly
dc.contributor.authorLlatjós, Roger
dc.contributor.authorBlasco Lucas, Arnau
dc.contributor.authorKuguel, Sebastián G.
dc.contributor.authorSbraga, Fabrizio
dc.contributor.authorGalli, Cesare
dc.contributor.authorPadler-Karavani, Vered
dc.contributor.authorTourneau, Thierry Le
dc.contributor.authorVadori, Marta
dc.contributor.authorPerota, Andrea
dc.contributor.authorRoussel, Jean-Christian
dc.contributor.authorBottio, Tomaso
dc.contributor.authorCozzi, Emanuele
dc.contributor.authorSoulillou, Jean Paul
dc.contributor.authorGaliñanes, Manuel
dc.contributor.authorMáñez, Rafael
dc.contributor.authorCosta, Cristina
dc.date.accessioned2023-10-09T12:08:09Z
dc.date.available2023-10-09T12:08:09Z
dc.date.issued2023-07-13
dc.date.updated2023-08-17T08:37:00Z
dc.description.abstractStructural valve deterioration (SVD) of bioprosthetic heart valves (BHVs) has great clinical and economic consequences. Notably, immunity against BHVs plays a major role in SVD, especially when implanted in young and middle-aged patients. However, the complex pathogenesis of SVD remains to be fully characterized, and analyses of commercial BHVs in standardized-preclinical settings are needed for further advancement. Here, we studied the immune response to commercial BHV tissue of bovine, porcine, and equine origin after subcutaneous implantation into adult a1,3-galactosyltransferase-knockout (Gal KO) mice. The levels of serum anti-galactose a1,3-galactose (Gal) and -non-Gal IgM and IgG antibodies were determined up to 2 months post-implantation. Based on histological analyses, all BHV tissues studied triggered distinct infiltrating cellular immune responses that related to tissue degeneration. Increased anti-Gal antibody levels were found in serum after ATS 3f and Freedom/Solo implantation but not for Crown or Hancock II grafts. Overall, there were no correlations between cellular-immunity scores and post-implantation antibodies, suggesting these are independent factors differentially affecting the outcome of distinct commercial BHVs. These findings provide further insights into the understanding of SVD immunopathogenesis and highlight the need to evaluate immune responses as a confounding factor.
dc.format.extent18 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2306-5354
dc.identifier.pmid37508860
dc.identifier.urihttps://hdl.handle.net/2445/202708
dc.language.isoeng
dc.publisherMDPI AG
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/bioengineering10070833
dc.relation.ispartofBioengineering, 2023, vol. 10, num. 7
dc.relation.urihttps://doi.org/10.3390/bioengineering10070833
dc.rightscc by (c) Casós, Kelly et al., 2023
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationPròtesis valvulars cardíaques
dc.subject.classificationResposta immunitària
dc.subject.otherHeart valve prosthesis
dc.subject.otherImmune response
dc.titleDifferential Immune Response to Bioprosthetic Heart Valve Tissues in the α1,3Galactosyltransferase-Knockout Mouse Model
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
bioengineering-10-00833.pdf
Mida:
4.79 MB
Format:
Adobe Portable Document Format